We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-2.1%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$5.12B
AUM Growth
-$506M
(-9%)
Cap. Flow
-$1.33B
Cap. Flow
% of AUM
-25.88%
Top 10 Holdings %
Top 10 Hldgs %
36.5%
Holding
171
New
28
Increased
20
Reduced
18
Closed
38
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NUVL
Nuvalent
NUVL
|
+$561M |
| 2 |
GeneDx Holdings
WGS
|
+$144M |
| 3 |
Neurocrine Biosciences
NBIX
|
+$39.4M |
| 4 |
Glaukos
GKOS
|
+$34.3M |
| 5 |
AERI
Aerie Pharmaceuticals
AERI
|
+$31.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$54.4M |
| 2 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$54.1M |
| 3 |
QuidelOrtho
QDEL
|
+$52.4M |
| 4 |
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
|
+$45.3M |
| 5 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
+$42.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.12% |
| 2 | Financials | 1.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KALV
26
DELISTED
KalVista Pharmaceuticals
KALV
| $37.8M | 0.74% |
2,163,554
| – | – |
|
27
Nuvation Bio
NUVB
$2.02B
| $35.6M | 0.69% |
3,577,233
| – | – |
|
|
AERI
28
DELISTED
Aerie Pharmaceuticals
AERI
| $33.9M | 0.66% |
2,977,020
+2,151,083
| +260% | +$31.4M |
|
|
BDSI
29
DELISTED
BioDelivery Sciences International, Inc.
BDSI
| $33.1M | 0.65% |
9,170,699
-359,301
| -4% | -$1.36M |
|
30
Brookdale Senior Living
BKD
$3.58B
| $33.1M | 0.65% |
5,252,800
+1,954,800
| +59% | +$14M |
|
|
SWTX
31
DELISTED
SpringWorks Therapeutics
SWTX
| $32.4M | 0.63% |
510,673
-47,901
| -9% | -$3.69M |
|
32
Werewolf Therapeutics
HOWL
$17.9M
| $30.1M | 0.59% |
1,752,787
-800,000
| -31% | -$13.7M |
|
|
33
Glaukos
GKOS
$9.21B
| $29.8M | 0.58% |
+619,000
| New | +$34.3M |
|
|
ONCR
34
DELISTED
Oncorus, Inc.
ONCR
| $29.4M | 0.57% |
3,148,977
| – | – |
|
35
Pharvaris
PHVS
$2.44B
| $28.5M | 0.56% |
1,608,471
+575,714
| +56% | +$9.85M |
|
|
DCPH
36
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $27.7M | 0.54% |
815,000
-528,560
| -39% | -$16.9M |
|
|
INZY
37
DELISTED
Inozyme Pharma
INZY
| $27.2M | 0.53% |
2,344,786
+165,801
| +8% | +$2.59M |
|
38
Rhythm Pharmaceuticals
RYTM
$7.31B
| $26M | 0.51% |
1,989,625
| – | – |
|
|
XLRN
39
DELISTED
Acceleron Pharma
XLRN
| $25M | 0.49% |
145,000
-74,500
| -34% | -$9.74M |
|
40
Protagonist Therapeutics
PTGX
$9.06B
| $24.7M | 0.48% |
1,394,000
+31,210
| +2% | +$1.33M |
|
|
TERN
41
DELISTED
Terns Pharmaceuticals
TERN
| $24.4M | 0.48% |
2,345,959
| – | – |
|
42
Alector
ALEC
$167M
| $24.1M | 0.47% |
1,055,192
| – | – |
|
43
PMV Pharmaceuticals
PMVP
$71.5M
| $24M | 0.47% |
804,000
| – | – |
|
|
KNTE
44
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $23.7M | 0.46% |
1,028,508
+8,508
| +0.8% | +$185K |
|
45
Cullinan Oncology
CGEM
$1.09B
| $23.6M | 0.46% |
1,044,000
| – | – |
|
|
AFIB
46
DELISTED
Acutus Medical Inc
AFIB
| $23.4M | 0.46% |
2,648,386
-1,693,413
| -39% | -$22.3M |
|
|
VINC
47
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
| $22.3M | 0.44% |
+68,966
| New | +$20.1M |
|
48
Fate Therapeutics
FATE
$324M
| $21.5M | 0.42% |
362,000
+58,000
| +19% | +$4.55M |
|
|
ITMR
49
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
| $21M | 0.41% |
694,667
-499,136
| -42% | -$11M |
|
50
Instil Bio
TIL
$50.3M
| $19.9M | 0.39% |
55,787
| – | – |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q3 2021 Portfolio in Review
As of Q3 2021, Deerfield Management held 171 positions worth $5.12B, down 9% from $5.63B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
Deerfield Management withdrew a net $1.33B in Q3 2021, closing 38 positions and reducing 18 holdings. Its most notable exit was Zimmer Biomet, an estimated $54.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 68% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Nuvalent worth $436M.
- Deerfield Management's largest Q3 2021 buy was Nuvalent: 19,341,024 shares worth $436M.
- Deerfield Management added most to Neurocrine Biosciences in Q3 2021, an estimated $39.4M increase.
- Deerfield Management's biggest Q3 2021 reduction was BioCryst Pharmaceuticals, cutting an estimated $41M.
- Deerfield Management fully exited Zimmer Biomet in Q3 2021, selling an estimated $54.4M.
- Deerfield Management's ten largest holdings make up 37% of its $5.12B portfolio in Q3 2021.
- Deerfield Management opened 28 new positions and closed 38 in Q3 2021.
- Deerfield Management's portfolio value fell 9% quarter-over-quarter to $5.12B.
Based on Deerfield Management's 13F filing for Q3 2021, filed 15 Nov 2021.